Bevacizumab Efficacy and Tolerability in Patients with Metastatic Platinum-Sensitive Ovarian Cancer Beyond Progression
Many studies have shown the effectiveness and survival benefit of bevacizumab in epithelial ovarian cancer. In contrast, the literature offers limited studies addressing the survival benefits of continuing bevacizumab beyond disease progression. However, our study indicates that continuing bevacizumab beyond progression significantly contributes to both OS (p < 0.001) and PFS (p < 0.001). As larger studies with similar results to ours are conducted in the future, current guidelines may improve, and the decision to continue bevacizumab treatment after progression may become more evidence-based.
Authors
- Şaban Seçmeler (ORCID: https://orcid.org/0000-0001-8421-9234)
- Kayhan Ertürk (ORCID: https://orcid.org/0000-0001-5804-6800)
- Mert Erciyestepe (ORCID: https://orcid.org/0000-0002-7590-6101)
- Muhammed Mustafa Atçı (ORCID: https://orcid.org/0000-0002-1300-3695)
- Emir Çelik (ORCID: https://orcid.org/0000-0001-8440-3082)
- Aslı Büyükkuşcu (ORCID: https://orcid.org/0000-0001-9828-685X)
- Sezgi Güllü Erciyestepe
- Şermin Dinç Sonuşen (ORCID: https://orcid.org/0009-0003-0624-1462)
- Ahmet Emin Öztürk (ORCID: https://orcid.org/0000-0003-3365-5540)
- Okan Aydın (ORCID: https://orcid.org/0000-0002-9516-992X)
Institutions
- Istanbul Bilim University (TR)
- Istanbul Eye Hospital (TR)
Publication Details
- Journal
- Cancer Management and Research
- Published
- 2025-08-01
- DOI
- https://doi.org/10.2147/cmar.s531276
- Citations
- 1
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.70